Paper Details

  1. Home
  2. Paper Details

Long-Term Effect of Erlotinib Therapy in the Third Line of Anticancer Treatment in a Patient with Non-Small-Cell Lung Cancer - a Case Report.

Author: BratKristián, JakubíkováLenka, ŠťastnáNela

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This article discusses the treatment of malignant tumors of the trachea, lungs, and bronchus in the Czech Republic, focusing on the use of tyrosine kinase inhibitors (TKIs). TKIs are targeted therapies that can be effective in treating non-small-cell lung cancer with specific mutations. The article highlights the importance of early diagnosis and treatment with appropriate TKIs to improve prognosis for patients with these tumors.
Paper Details　
Original Abstract of the Article :
Malignant tumours of the trachea, the lungs, and the bronchus are the second most common type of tumour in the Czech Republic. Approximately three-quarters of cases are dia-gnosed in an advanced stage (IIIB-IV) and are one of the most common causes of death in all cancer groups. Targeted therapy bri...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.14735/amko2020226

データ提供：米国国立医学図書館（NLM）

Long-Term Effects of Erlotinib Therapy in Lung Cancer

The field of oncology is constantly striving to improve the outcomes for patients battling lung cancer, a formidable foe. This research delves into the long-term effects of erlotinib therapy in patients with non-small-cell lung cancer (NSCLC), a common type of lung cancer. Using a case report approach, the authors examined the effects of erlotinib therapy as a third-line treatment option. This study highlights the potential benefits of targeted therapy in improving the prognosis of NSCLC patients. A key takeaway is the importance of considering erlotinib as a viable option in later lines of treatment.

Erlotinib Therapy Shows Promise for Advanced Lung Cancer

The study demonstrated that erlotinib can be effective in the third-line treatment of NSCLC, offering hope to patients who have exhausted other treatment options. Although this research focused on a single patient case, the findings suggest that erlotinib may provide a valuable therapeutic avenue for a subset of NSCLC patients.

Understanding the Role of Targeted Therapies in Cancer Treatment

Targeted therapies, like erlotinib, work by specifically targeting certain proteins or pathways involved in cancer cell growth. This approach offers the potential for more effective treatment with fewer side effects compared to traditional chemotherapy. This research sheds light on the importance of considering targeted therapies as part of a comprehensive treatment plan for lung cancer.

Dr.Camel's Conclusion

As a seasoned researcher, I've witnessed the transformative power of targeted therapies in the fight against cancer. This study reminds us that even in the face of advanced disease, there is still hope. Erlotinib represents a beacon of progress in the field of oncology, and I am hopeful that future research will continue to expand its application and refine its effectiveness for patients with lung cancer.

Date :
  1. Date Completed 2021-05-28
  2. Date Revised 2021-05-28
Further Info :

Pubmed ID

32683880

DOI: Digital Object Identifier

10.14735/amko2020226

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.